Maria Jastrzebska1, Iwona Goracy, Marek Naruszewicz. 1. Department of Clinical Biochemistry and Laboratory Diagnostics, Pomeranian Medical University, Al Powstańców Wlkp 72, 70-111 Szczecin, Poland.
Abstract
BACKGROUND: To elucidate the role of some haemostatic gene polymorphisms and environmental factors, we studied fibrinogen (Fb), plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) levels with respect to Fb G455A and PAI-1 4G/5G gene polymorphisms in smokers and nonsmokers with essential hypertension. MATERIAL AND METHODS: The study was done in 90 patients (including 30 smokers) with essential hypertension (HT) and 40 controls (including 8 smokers). Fb and PAI-1 genotypes were PCR identified. The groups did not differ significantly as to genotype frequencies. RESULTS: When allele A455 carriers were compared, HT patients had significantly higher Fb (p=0.015) and t-PA levels (p=0.013). Comparison of 4G allele carriers (4G/4G homozygotes) revealed significantly higher Fb (p=0.045), PAI-1 (p=0.009), and t-PA levels (p=0.007) in HT patients than controls. Interactions of Fb and PAI-1 gene polymorphisms with smoking were disclosed in HT patients only. Allele A455-carrying HT smokers compared with nonsmokers had significantly higher t-PA (12.1 +/- 5.8 vs. 7.4 +/- 3.1 ng/ml; p=0.002) and tendency to higher Fb (3.36 +/- 0.74 vs. 2.95 +/- 0.70 g/l; p=0.075) levels. Higher Fb levels were disclosed in 4G/4G smokers than nonsmokers (3.31 +/- 0.81 vs. 2.84 +/- 0.85 g/l; p=0.064). Finally, in smokers, significantly higher levels of PAI-1 were found in 4G/4G (42.1 +/- 29.4 ng/ml) as compared with 4G/5G (18.6 +/- 13.7 ng/ml; p=0.025) and 5G/5G (14.4 +/- 10.8 ng/ml; p=0.044) genotypes. CONCLUSIONS: Smoking potentiates the prothrombotic effect of allele A455 and PAI-1 4G/4G genotype in untreated essential hypertension, reflected by increased levels of haemostatic risk factors and accelerated progression of cardiovascular diseases.
BACKGROUND: To elucidate the role of some haemostatic gene polymorphisms and environmental factors, we studied fibrinogen (Fb), plasminogen activator inhibitor-1 (PAI-1), and tissue plasminogen activator (t-PA) levels with respect to FbG455A and PAI-1 4G/5G gene polymorphisms in smokers and nonsmokers with essential hypertension. MATERIAL AND METHODS: The study was done in 90 patients (including 30 smokers) with essential hypertension (HT) and 40 controls (including 8 smokers). Fb and PAI-1 genotypes were PCR identified. The groups did not differ significantly as to genotype frequencies. RESULTS: When allele A455 carriers were compared, HTpatients had significantly higher Fb (p=0.015) and t-PA levels (p=0.013). Comparison of 4G allele carriers (4G/4G homozygotes) revealed significantly higher Fb (p=0.045), PAI-1 (p=0.009), and t-PA levels (p=0.007) in HTpatients than controls. Interactions of Fb and PAI-1 gene polymorphisms with smoking were disclosed in HTpatients only. Allele A455-carrying HT smokers compared with nonsmokers had significantly higher t-PA (12.1 +/- 5.8 vs. 7.4 +/- 3.1 ng/ml; p=0.002) and tendency to higher Fb (3.36 +/- 0.74 vs. 2.95 +/- 0.70 g/l; p=0.075) levels. Higher Fb levels were disclosed in 4G/4G smokers than nonsmokers (3.31 +/- 0.81 vs. 2.84 +/- 0.85 g/l; p=0.064). Finally, in smokers, significantly higher levels of PAI-1 were found in 4G/4G (42.1 +/- 29.4 ng/ml) as compared with 4G/5G (18.6 +/- 13.7 ng/ml; p=0.025) and 5G/5G (14.4 +/- 10.8 ng/ml; p=0.044) genotypes. CONCLUSIONS: Smoking potentiates the prothrombotic effect of allele A455 and PAI-1 4G/4G genotype in untreated essential hypertension, reflected by increased levels of haemostatic risk factors and accelerated progression of cardiovascular diseases.
Authors: M G Sherenian; S H Cho; A Levin; J-Y Min; S S Oh; D Hu; J Galanter; S Sen; S Huntsman; C Eng; J R Rodriguez-Santana; D Serebrisky; P C Avila; R Kalhan; L J Smith; L N Borrell; M A Seibold; L Keoki Williams; E G Burchard; R Kumar Journal: Clin Exp Allergy Date: 2017-07-03 Impact factor: 5.018